Correction: Amygdala reactivity to threat, negative facial perception, and risk of future psychiatric hospitalizations: a longitudinal study in major depressive and bipolar disorders
Publication date: August 2026 Source: Neuropsychopharmacology, Volume 51, Issue 9 Author(s): Kamilla W. Miskowiak, Brice Ozenne, Hanne L. Kjærstad, Patrick M. Fisher, Emily E. Beaman, Vibeke H. Dam, Alexander T. Ysbæk-Nielsen, Gitte M. Knudsen, Lars V. Kessing, Julian Macoveanu, Vibe G. Frøkjær, Anjali Sankar
Correction: Amygdala reactivity to threat, negative facial perception, and risk of future psychiatric hospitalizations: a longitudinal study in major depressive and bipolar disorders. // Neuropsychopharmacology. – URL: https://www.sciencedirect.com/science/article/pii/S0893133X26008730?dgcid=rss_sd_all
Correction: Amygdala reactivity to threat, negative facial perception, and risk of future psychiatric hospitalizations: a longitudinal study in major depressive and bipolar disorders. Neuropsychopharmacology. https://www.sciencedirect.com/science/article/pii/S0893133X26008730?dgcid=rss_sd_all
“Correction: Amygdala reactivity to threat, negative facial perception, and risk of future psychiatric hospitalizations: a longitudinal study in major depressive and bipolar disorders.” Neuropsychopharmacology.
@article{article119299,
title = {Correction: Amygdala reactivity to threat, negative facial perception, and risk of future psychiatric hospitalizations: a longitudinal study in major depressive and bipolar disorders},
journal = {Neuropsychopharmacology},
url = {https://www.sciencedirect.com/science/article/pii/S0893133X26008730?dgcid=rss_sd_all}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...